Immunic, Inc. (NASDAQ:IMUX) is expected to report second quarter earnings results, before market open, on Monday 3rd August 2020.
Analysts polled by Thomson Reuters anticipate second quarter loss of $ 0.69 per share.
Looking ahead, the full year loss are expected at $ 2.73 per share.
Previous Quarter Performance
Immunic, Inc. recorded loss for the first quarter of $ 0.79 per share, from the revenue of , On adjusted basis, IMUX reported for the quarter of per share. The quarterly revenues compared with the same quarter last year. According to street consensus, revenue of was expected for the first quarter The bottom line results street analysts by $ 0.06 or , at the same time, top line results analysts by $ 0.16 million or .
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Stock Performance
According to the previous trading day, closing price of IMUX was $ 17.20, representing a 310.50 % increase from the 52 week low of $ 4.19 and a 3.43 % decrease over the 52 week high of $ 17.81.
The company has a market capital of $ 255.73 million and is part of the Healthcare sector and Biotechnology industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”IMUX” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Recent Analyst recommendations
- On 5th June 2020, initiated by Wedbush at Outperform rating.
Conference Call
Immunic, Inc. will be hosting a conference call at 8:30 AM eastern time on 3rd August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.immunic-therapeutics.com
Immunic, Inc., a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies for treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohns disease, relapsing-remitting multiple sclerosis, and psoriasis. Its lead development program is IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH, which is in phase II clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis. The company is also developing IMU-935, an inverse agonist of RORyt; and IMU-856 for the restoration of the intestinal barrier function.
